Search clinical trials for: ABT-335 and rosuvastatin calcium

Total 10932 results

AstraZeneca

Completed

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Dyslipidemia | Hypercholesterolemia

United States
Abbott

Completed

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
AstraZeneca

Completed

Interaction Between ABT-335, Rosuvastatin and Warfarin

Healthy

United States
AstraZeneca

Completed

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

Adverse Events | Pharmacokinetic

United States
AstraZeneca

Completed

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

Healthy

United States
AstraZeneca

Completed

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

Adverse Events | Pharmacokinetic Variables

United States
AstraZeneca

Completed

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

Healthy

United States
AstraZeneca

Completed

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Dyslipidemia | Kidney Disease

United States, Puerto Rico
AstraZeneca

Completed

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Dyslipidemia, Renal Insufficiency

United States
Abbott

Completed

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
AstraZeneca

Completed

Assessment of the Effect of Food on ABT-143 Bioavailability

Pharmacokinetic Variables

United States
Abbott

Completed

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Mixed Dyslipidemia

United States
Abbott

Completed

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

HCV Infection

United States
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Abbott

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

HCV Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
Affibody
Covance

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

Psoriasis | Healthy Subjects

United Kingdom
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

Healthy Subjects

Czechia
Makerere University
University of Oxford; Case Western Reserve University

Unknown

Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial (STAR)

HIV Infection
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

HCV Infection

United States, Puerto Rico
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
NVP Healthcare

Completed

to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers (NVP-1205)

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

Healthy Subjects

Czechia
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
University of Roma La Sapienza

Not yet recruiting

A Prospective muLticEnter Registry in chrONic coronARy synDrOme (LEONARDO)

Coronary Artery Disease
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Statin and Atheroma Vulnerability Evaluation (STABLE)

Coronary Artery Disease

Korea, Republic of
Nanjing First Hospital, Nanjing Medical University

Unknown

Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin (CROWN-1)

Acute Coronary Syndrome

China
Shanghai Zhongshan Hospital

Unknown

Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)

Non-ST-elevation Acute Coronary Syndromes

China
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
University of Roma La Sapienza

Unknown

Rosuvastatin for Preventing Complications in Renal Ablation (ARTEMISIA)

Arterial Hypertension

Italy
Affibody

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

Psoriasis

United States
Cross Research S.A.
Zambon SpA

Completed

Safinamide Steady State Interaction With Rosuvastatin

Healthy

Switzerland
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
AstraZeneca

Completed

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Familial Hypercholesterolaemia

United States, Netherlands, Norway, Canada, Belgium
Erasmus Medical Center

Terminated

Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders (ATTENTIO)

Generalized Anxiety Disorder | Social Anxiety Disorder | Specific Phobia | Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood, Early Onset

Netherlands
Ottawa Hospital Research Institute

Unknown

StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study (SAVER)

Venous Thromboembolism

Canada, Norway
EMS

Recruiting

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Dyslipidemia Associated With Type II Diabetes Mellitus

Brazil
AstraZeneca

Completed

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

Coronary Arteriosclerosis

United States, Australia, France, Italy, Spain, Belgium, Canada, Netherlands
Gonzalez-Heydrich, Joseph, M.D.

Unknown

Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger

Anger | Aggression

United States
AstraZeneca

Completed

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

Hypercholesteremia

United States, France, Norway, Netherlands, Belgium, Germany, Finland, Czech Republic
EMS

Not yet recruiting

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Type 2 Diabetes Mellitus | Dyslipidemia
National Institute of Diabetes and Digestive and...
National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaborators

Recruiting

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (LCN RESCU)

Cirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing Cholangitis

United States
Kobe University

Unknown

Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound (ANTARES)

Coronary Artery Disease | Angina Pectoris

Japan
Kobe University

Completed

Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial

Coronary Artery Disease Progression

3

Subscribe